Compare
DocGo Inc. vs Omada Health, Inc. vs GeneDx Holdings Corp. vs Strata Critical Medical, Inc.
| Latest fiscal year | DocGo Inc. DCGO | Omada Health, Inc. OMDA | GeneDx Holdings Corp. WGS | Strata Critical Medical, Inc. SRTA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $322.20M | $260.21M | $427.54M | $197.14M |
| Revenue growth (YoY) | -47.7% | +53.2% | +40.0% | +34.3% |
| Gross margin | n/a | 65.7% | 69.7% | 20.9% |
| Operating margin | -55.3% | -4.6% | -3.1% | -11.3% |
| Net margin | -56.6% | -4.9% | -4.9% | 21.0% |
| Net income | -$182.40M | -$12.78M | -$21.02M | $41.35M |
| EPS (Diluted) | -$1.84 | -$0.35 | -$0.73 | $0.50 |
| Operating cash flow | $34.45M | $18.25M | $33.28M | -$48.91M |
| Free cash flow | $29.91M | $16.93M | $14.26M | -$58.51M |
| Cash & equivalents | $51.02M | $222.04M | $105.00M | $30.97M |
| Total assets | $217.10M | $305.41M | $523.71M | $325.47M |
| Total liabilities | $91.23M | $75.73M | $215.53M | $46.40M |
| Shareholders' equity | $144.01M | $229.68M | $308.18M | $279.07M |
| Return on year-end equity | -126.7% | -5.6% | -6.8% | 14.8% |
| Shares outstanding | 98.64M | 58.43M | 29.25M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | DocGo Inc. | Omada Health, Inc. | GeneDx Holdings Corp. | Strata Critical Medical, Inc. |
|---|---|---|---|---|
| Latest | $322.20M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $427.54M Ended 2025-12-31 | $197.14M Ended 2025-12-31 |
| 1 year earlier | $616.56M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $305.45M Ended 2024-12-31 | $146.82M Ended 2024-12-31 |
| 2 years earlier | $624.29M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $202.57M Ended 2023-12-31 | $225.18M Ended 2023-12-31 |
| 3 years earlier | $440.52M Ended 2022-12-31 | n/a | $234.69M Ended 2022-12-31 | $146.12M Ended 2022-12-31 |
| 4 years earlier | $318.72M Ended 2021-12-31 | n/a | $212.19M Ended 2021-12-31 | n/a |